Microcap Ledger Jaguar Health, Inc. $JAGX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- San Francisco, CA
- Fiscal year end
- December 31
What the company doesAI summary of filing
Jaguar Health, Inc. develops prescription drugs derived from plants to treat gastrointestinal diseases. The company's main revenue-generating product is Mytesi (crofelemer), an FDA-approved prescription drug for noninfectious diarrhea in HIV/AIDS patients, which was licensed to Future Pak in January 2026. The company is also developing crofelemer powder for oral solution for rare intestinal failure conditions (microvillus inclusion disease and short bowel syndrome), a second-generation drug called NP-300 for infectious diarrhea including cholera, and Gelclair, an oral mucositis product launched in October 2024. Jaguar also operates Magdalena Biosciences, a joint venture developing plant-based medicines for mental health conditions. [10-K 2026-04-07]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $21.50M | −$4.08M | $3.49M | $3.79M | [10-Q 2026-08-19] |
| FY ended Dec 2025 | $11.51M | −$54.0K | −$23.69M | $968.0K | [10-K 2026-04-07] |
| FY ended Dec 2024 | $11.69M | −$39.3K | −$29.38M | $8.00M | [10-K 2026-04-07] |
Capital structure and dilution
- Shelf registration
- S-1 filed 2026-07-16; declared effective 2026-08-14 [S-1 2026-07-16]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-05-04. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-05-04 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-04] |
| 2026-04-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-04-27] |
| 2026-03-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-06] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2025-12-11 | Micek John | grant | 7,377 | — | [4 2026-03-12] |
| 2025-12-11 | King Steven R. | grant | 11,740 | — | [4 2026-01-21] |
| 2025-12-11 | Conte Lisa A | grant | 28,592 | — | [4 2026-01-21] |
| 2025-12-11 | Wolin Jonathan S. | grant | 11,740 | — | [4 2026-01-21] |
| 2025-12-11 | Chaturvedi Pravin R | grant | 11,740 | — | [4 2025-12-15] |
| 2025-12-11 | Bochnowski James J | grant | 6,363 | — | [4 2025-12-15] |
| 2025-12-11 | Siegel Jonathan B. | grant | 7,377 | — | [4 2025-12-15] |
| 2025-12-11 | Jayasuriya Anula | grant | 5,870 | — | [4 2025-12-15] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-08 | DEF 14A | Proxy statement |
| 2026-10-05 | 8-K | Material agreement entered; New financial obligation; Change to security holder rights |
| 2026-09-28 | 8-K | Material agreement entered; Unregistered sale of equity; Other events |
| 2026-09-25 | 8-K | Material agreement entered; Material agreement terminated; Unregistered sale of equity |
| 2026-09-24 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-09-24 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-24 | 8-K | Material agreement entered; Unregistered sale of equity; Other events |
| 2026-09-21 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Other events |
| 2026-09-18 | PRE 14A | Proxy statement |
| 2026-09-15 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-09-15 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Regulation FD disclosure |
| 2026-09-04 | 8-K | Other events |
Alerts for $JAGX
Email me when Jaguar Health, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.